scholarly journals Transcriptome and genome analysis of single disseminated tumor cells: approach to study minimal residual cancer

10.1038/87156 ◽  
2001 ◽  
Vol 27 (S4) ◽  
pp. 65-65
Author(s):  
Christoph Klein ◽  
Stefan Seidl ◽  
Karina Petat-Dutter ◽  
Oleg Schmidt-Kittler ◽  
Sonja Offner ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Genome Analysis ◽  
Disseminated Tumor Cells ◽  
Residual Cancer ◽  
Minimal Residual Cancer ◽  
Minimal Residual

scholarly journals Minimal Residual Cancer Detection in Hematopoietic Stem Cell Products and its Prognostic Significance in Patients with Breast Cancer, Lymphoma, or Multiple Myeloma

1998 ◽  
Vol 5 (5) ◽  
pp. 406-414
Author(s):  
Thomas J. Moss
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Tumor Cells ◽  
Published Data ◽  
High Dose ◽  
Cell Detection ◽  
Residual Cancer ◽  
Hematopoietic Stem ◽  
Minimal Residual Cancer ◽  
Minimal Residual

Background Despite the initial success of high-dose therapy and bone marrow transplant, the major reason for posttransplant failure is relapse of disease. Reinfusion of tumor cells may contribute to relapse in autologous stem cell transplants. We now have ultra-sensitive methods of tumor cell detection that can determine the presence of minimal residual cancer (MRC) in marrow and peripheral blood stem cells. Methods The author has conducted a critical review of the literature on this issue. Results The factors that are associated with an increase in contamination of the graft include (1) the number of cycles of induction therapy, (2) the type of mobilization regimen used, (3) the presence of tumor cells in the marrow, and (4) the number of phereses. A number of studies show that the presence of occult breast cancer in the marrow and/or stem cell product predicts for a poor posttransplant clinical outcome. The presence of clonogenic breast cancer or lymphoma cells in the graft is also associated with a very poor outcome. Published data regarding contamination in graft and outcome for patients with myeloma are limited. Conclusions Testing for minimal MRC in the oncology patient provides prognostic information that may be useful to the transplant physician.

scholarly journals Minimal Residual Disease, Metastasis and Immunity

Biomolecules ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 130
Author(s):  
Jordi Badia-Ramentol ◽  
Jenniffer Linares ◽  
Andrea Gómez-Llonin ◽  
Alexandre Calon
Keyword(s):  
Cancer Cells ◽  
Tumor Cells ◽  
Minimal Residual Disease ◽  
Cancer Progression ◽  
Residual Disease ◽  
Disseminated Tumor Cells ◽  
Curative Therapy ◽  
Cancer Dormancy ◽  
Distant Tissue ◽  
Minimal Residual

Progression from localized to metastatic disease requires cancer cells spreading to distant organs through the bloodstream. Only a small proportion of these circulating tumor cells (CTCs) survives dissemination due to anoikis, shear forces and elimination by the immune system. However, all metastases originate from CTCs capable of surviving and extravasating into distant tissue to re-initiate a tumor. Metastasis initiation is not always immediate as disseminated tumor cells (DTCs) may enter a non-dividing state of cell dormancy. Cancer dormancy is a reversible condition that can be maintained for many years without being clinically detectable. Subsequently, late disease relapses are thought to be due to cancer cells ultimately escaping from dormant state. Cancer dormancy is usually associated with minimal residual disease (MRD), where DTCs persist after intended curative therapy. Thus, MRD is commonly regarded as an indicator of poor prognosis in all cancers. In this review, we examine the current understanding of MRD and immunity during cancer progression to metastasis and discuss clinical perspectives for oncology.

Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow

2002 ◽  
Vol 20 (8) ◽  
pp. 2005-2016 ◽  
Author(s):  
Markus Maria Heiss ◽  
Erich H. Simon ◽  
Bianca C.M. Beyer ◽  
Klaus Uwe Gruetzner ◽  
Anwar Tarabichi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Bone Marrow ◽  
Overall Survival ◽  
Tumor Cells ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Disseminated Tumor Cells ◽  
Primary Surgery ◽  
Disease Free ◽  
Minimal Residual

PURPOSE: To study the invasion-related molecule urokinase-type plasminogen activator receptor (u-PAR) expressed by disseminated tumor cells as a biologic predictor of poor survival in a large prospective series of patients with gastric cancer. PATIENTS AND METHODS: In 156 gastric cancer patients (prospective series), disseminated tumor cells in the bone marrow and the u-PAR expressed by these tumor cells were determined by cytokeratin (CK) 18 immunocytochemistry and u-PAR/CK18 double immunocytochemistry. RESULTS: In contrast to the mere detection of disseminated tumor cells at primary surgery, the additional evidence of u-PAR on these cells correlated significantly with pathologic T stage (P = .0474) and the expression of u-PAR (P = .0093) and plasminogen-activator inhibitor 1 (P = .0145) in the primary tumor (immunohistochemistry, χ2). Kaplan-Meier analysis revealed no association with prognosis for the mere detection of disseminated tumor cells. In contrast, a significant association was seen between detection of u-PAR on these cells and shorter disease-free (P < .0001) and overall survival (P < .0001). Multivariate analysis revealed that u-PAR on disseminated tumor cells at the time of primary surgery is an independent prognostic factor for disease-free (95% confidence interval [CI], 1.72 to 3.21; P = .024) and overall survival (P = .0049; relative risk, 2.89; 95% CI, 1.92 to 4.30). CONCLUSION: This is the first large study to show that u-PAR, detected on disseminated tumor cells in the bone marrow, is an independent prognostic parameter in gastric cancer, in contrast to the mere detection of minimal residual disease (MRD). u-PAR may be a promising marker to define a critical subpopulation of disseminated tumor cells and a target to eliminate MRD. Molecular phenotyping of MRD is critical for defining its individual clinical relevance.

scholarly journals Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer

2021 ◽  
Author(s):  
Dongbin Zhao ◽  
Pinli Yue ◽  
Tongbo Wang ◽  
Pei Wang ◽  
Qianqian Song ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Cancer Cells ◽  
Peritoneal Lavage ◽  
Peritoneal Dissemination ◽  
Lavage Fluid ◽  
Residual Cancer ◽  
Peritoneal Lavage Fluid ◽  
Minimal Residual Cancer ◽  
Minimal Residual

Abstract Peritoneal dissemination (PD) is the major type of gastric cancer (GC) recurrence and leads to rapid death. Current approach cannot precisely determine which patients are at high risk of PD. In this study, we developed a technology to detect minimal residual cancer cells in peritoneal lavage fluid (PLF) samples by parallel profiling tumor-specific mutations. We applied the technology to a prospective cohort of 110 GC patients. The technology showed ultra-high sensitivity by successfully detecting all the 27 cases that developed PD. The minimal residual cancer cells in PLF was associated with an increased risk of PD (HR = 145.13; 95%CI = 20.20-18435.79; p < 0.001) and significantly shorter overall survival. In pathologically high-risk (T4) patients, the PLF mutation profiling model exhibited even greater specificity of 91% and positive predictive value of 88%, while retaining sensitivity of 100%. PLF cancer cell fraction remained the strongest independent predictor of PD and recurrence-free survival over pathologic diagnosis and cytological diagnosis in GC patients. This approach may help in the postsurgical management of GC patients by detecting PD far before the metastatic lesions grow to significant size detectable by conventional methods such as MRI and CT scanning.

Sign in / Sign up

Export Citation Format

Share Document